Aduvant therapy of depression with hopantenic acid-Reference-Cited by-同舟云学术

Aduvant therapy of depression with hopantenic acid

Published:2022-01-09 Issue:41 Volume: Page:6-10
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Medvedev V. E.¹^ORCID

Affiliation:

1. Peoples' Friendship University of Russia; Clinical Hospital of the Administrative Department of the President of Russia; International Institute for Psychosomatic Health

Abstract

Adequate SSRI monotherapy does not produce a sufficient clinical effect in some patients, and about 30% of patients do not respond to therapy at all. Favorable experience of combined prescription of SSRIs with various nootropic (neuroprotective) agents has been described in the literature.The aim of the study was to investigate the efficacy and tolerability of hopantenic acid as an adjuvant therapy for depression. We obtained significant data that inclusion of hopantenic acid at a dose of 2000 mg per day in a 12-week complex antidepressant therapy with paroxetine (20 mg per day) statistically significantly reduces the severity of depression symptoms. The drug's effect is achieved by improving patients' cognitive functions, reducing anxiety symptoms and side effects of SSRIs. Improved efficacy and tolerability of antidepressant therapy with hopantenic acid in the long term will allow to achieve more significant improvement in the quality of life of patients.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference23 articles.

1. Cowen P.J. New drugs, old problems. Revisiting… Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment. 2005: 11.

2. Stahl S.M. Serotonin antagonism and reuptake inhibition; pharmacology and physiology of CNS serotonin housekeeping. Int J Neuropsychopharmacology. 2004: 7 (Suppl. 1): 117.

3. Medvedev V.E., Frolova V.I., Ter-Israelyan A. Yu., Korovyakova E.A., Gushanskaya E. V. Therapy of depressive disorders occurring with circanual rhythms. Psychiatry and psychopharmacotherapy. 2018; 20 (5): 38–43.

4. V.E. Medvedev Post-marketing study of the safety and efficacy of Elycea (escitalopram) in the treatment of depressive and anxiety disorders (abstract). Psychiatry and psychopharmacotherapy. 2013; 4: 65–68.

5. V.E. Medvedev Lenuxin in the treatment of depression. Psychiatry and psychopharmacotherapy. 2012; 4: 42–45.